We tried to validate the association between TP53 mutations and prognosis, including response to chemotherapy, in the TCGA cohort, but the validation was difficult because of the insufficient prognostic follow-up period, the extremely small number of cases in many cancer types when matched for case background (age, sex, stage, etc.)between patients with wild-type and mutant TP53, and the lack of treatment data (treatment line, drugs, etc.). The gene discussed is TP53; the disease is cancer.